GLP-1 is the naturally produced hormone whose function is being mimicked by drugs like semaglutide and tirzepatide, the active ingredients in popular and highly effective weight-loss drugs like Wegovy ...

Please provide your email address to receive an email when new articles are posted on . A large cohort study showed high prevalence of bilateral diabetic macular edema at first visit. The intensity of ...

The cost of sequencing DNA has dropped dramatically, and with technologies like CRISPR, gene editing is becoming more precise and powerful than ever. From curing genetic diseases to designing the next ...

Cancer cells can brainwash their neighbors. Like the CIA deploying secret agents to turn an enemy, tumors use a similar strategy to manipulate nearby cells. The tumors’ agents are mitochondria, the ...

A first-in-class antisense oligonucleotide — RES-010 (Resalis Therapeutics, Turin, Italy) — may complement and enhance the efficacy of antiobesity drugs such as GLP-1 receptor agonists (RAs), ...

If you own a smart TV, then you probably have streamer buttons on your remote control. This handy feature allows you to easily jump from an app like Netflix to Disney+, without having to escape back ...

Less than a month ago, BMW announced a recall impacting more than 70,000 of its electric vehicles, revealing a software issue that could cause the high-voltage system to shut down unexpectedly. Fast ...

A new study led by researchers at Huntsman Cancer Institute at the University of Utah (the U) shows that regular exercise may do more than help colon cancer patients feel better—it may actually change ...

Garmin has introduced new remote-mount Distance Measuring Equipment (DME) radios, the GDM 4500 and GDM 450R, to provide slant-distance information and upgrade DME capabilities on various aircraft. The ...

Leafcutter ants live in highly organized colonies where every ant has a job, and now researchers can flip those jobs like a switch. By manipulating just two neuropeptides, scientists can turn ...

Ashvattha will present Phase 2 data on migaldendranib, a subcutaneous therapy for DME and wet AMD, which could offer a more patient-friendly alternative to current injection-based treatments Company ...